#BEGIN_DRUGCARD DB00832

# AHFS_Codes:
Not Available

# ATC_Codes:
N03AD02

# Absorption:
Rapid and complete.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
(+/-)-N-Methyl-2-phenylsuccinimide
1-Methyl-3-Phenylsuccinimide
Epimid
Fenosuccimide
Fensuccimide [DCIT]
Fensuximida [INN-Spanish]
Lifene
Methylphenylsuccinimide
Milontin
Milontin (TN)
Milonton
Mirontin
Mirotin;7 Phenosuccimide
N-Methyl-2-phenylsuccinimide
N-Methyl-alpha-phenolsuccinimide
N-Methyl-alpha-phenylsuccinimide
Phensuximid
Phensuximide (USP)
Phensuximide [BAN:INN]
Phensuximidum [INN-Latin]
Phenylsuximide
Succinimide, N-methyl-2-phenyl-
Succitimal

# CAS_Registry_Number:
86-34-0

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H11NO2

# Chemical_IUPAC_Name:
1-methyl-3-phenylpyrrolidine-2,5-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Phensuximide is an anticonvulsant in the succinimide class. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

# Dosage_Forms:
Not Available

# Drug_Category:
Anticonvulsants
Antiepileptic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
14020499	CHEN G, WESTON JK, BRATTON AC Jr: Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76.
3772011	Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI: Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56.
38736	Ferrendelli JA, Kinscherf DA: Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol. 1979 Jun;5(6):533-8.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7020 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Phensuximide

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3

# InChI_Key:
InChIKey=WLWFNJKHKGIJNW-UHFFFAOYSA-N

# Indication:
For the treatment of epilepsy.

# KEGG_Compound_ID:
C07437

# KEGG_Drug_ID:
D00508

# LIMS_Drug_ID:
832

# Mechanism_Of_Action:
Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue.

# Melting_Point:
72 Â°C

# Molecular_Weight_Avg:
189.2105

# Molecular_Weight_Mono:
189.078978601

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164771230

# Pharmacology:
Phensuximide suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

# Predicted_LogP_Hydrophobicity:
0.61

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
2.21e+00 g/l

# Primary_Accession_No:
DB00832

# Protein_Binding:
21%

# PubChem_Compound_ID:
6839

# PubChem_Substance_ID:
46505695

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00496

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN1C(=O)CC(C1=O)C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:40 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Phensuximide

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_1_ID:
6016

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P33261

#END_DRUGCARD DB00832
